Benefits of icosapent ethyl for enhancing residual cardiovascular risk reduction: A review of key findings from REDUCE-IT-Reference-Cited by-同舟云学术

Benefits of icosapent ethyl for enhancing residual cardiovascular risk reduction: A review of key findings from REDUCE-IT

Published:2022-07 Issue:4 Volume:16 Page:389-402
ISSN:1933-2874
Container-title:Journal of Clinical Lipidology
language:en
Short-container-title:Journal of Clinical Lipidology

Author:

Gaba Prakriti,Bhatt Deepak L.^ORCID,Mason R. Preston^ORCID,Miller Michael^ORCID,Verma Subodh,Steg Ph. Gabriel,Boden William E.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine,Nutrition and Dietetics,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference64 articles.

1. Hill MF., Bordoni B. Hyperlipidemia. In: StatPearls. Treasure Island (FL): StatPearls Publishing, 2022. Available at: http://www.ncbi.nlm.nih.gov/books/NBK559182/. Accessed February 15, 2022.

2. Association of hypertriglyceridemia with all-cause mortality and atherosclerotic cardiovascular events in a low-risk Italian population: the TG-REAL retrospective cohort analysis;Arca;J Am Heart Assoc,2020

3. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis;Yokoyama;Lancet N Am Ed,2007

4. Stabilizing effect of combined eicosapentaenoic acid and statin therapy on coronary thin-cap fibroatheroma;Nishio;Atherosclerosis,2014

5. Combination therapy of eicosapentaenoic acid and pitavastatin for coronary plaque regression evaluated by integrated backscatter intravascular ultrasonography (CHERRY study)-rationale and design;Watanabe;J Cardiol,2014

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Omega-3 eicosapentaenoic polar-lipid rich extract from microalgae Nannochloropsis decreases plasma triglycerides and cholesterol in a real-world normolipidemic supplement consumer population;Frontiers in Nutrition;2024-02-06

2. Fat and fatty acids – a scoping review for Nordic Nutrition Recommendations 2023;Food & Nutrition Research;2024-01-12

3. Riesgo residual. Conclusiones;Revista Española de Cardiología Suplementos;2023-11

4. Icosapent ethyl for hypertriglyceridaemia and atherosclerosis: greater RESPECT for increased therapeutic use;European Heart Journal;2023-10-27

5. Generalizability of REDUCE-IT eligibility criteria in a large diabetes cardiovascular outcomes trial: A post hoc subgroup analysis of EMPA-REG outcome;American Journal of Preventive Cardiology;2023-09